BJMO - volume 18, issue 6, october
G. Desimpel MD, E. Seront MD, PhD
The year 2023 marked a significant revolution in urothelial cancer, introducing novel anticancer strategies. The synergy between antibody-drug conjugates and immune checkpoint inhibitors has led to a drastic improvement in patient outcomes. Using this combination in first-line metastatic urothelial carcinoma has achieved a median overall survival exceeding 30 months, a milestone in the field. This breakthrough not only paves the way for a deeper comprehension of the disease’s pathogenesis but also underscores the pivotal role of combinations in urothelial carcinoma, applicable not only in advanced stages but also in the localised setting. This review serves as a reminder of the novel mechanism of action of these drugs, alongside highlighting their safety profile. Additionally, we emphasise the critical importance of refining patient selection criteria, particularly in the context of immune checkpoint inhibitors and bladder sparing strategies.
(BELG J MED ONCOL 2024;18(6):227-234)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
